{"id":70062,"date":"2026-07-16T15:47:42","date_gmt":"2026-07-16T07:47:42","guid":{"rendered":"https:\/\/flcube.com\/?p=70062"},"modified":"2026-07-16T15:47:43","modified_gmt":"2026-07-16T07:47:43","slug":"johnson-johnson-reports-q2-2026-results-with-6-6-sales-growth-raises-full-year-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70062","title":{"rendered":"Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance"},"content":{"rendered":"\n

Johnson & Johnson (J&J)<\/strong> (J&J, NYSE: JNJ<\/a>) announced second-quarter 2026 results, reporting sales growth of 6.6% year-over-year (YOY)<\/strong> to USD 25.3 billion<\/strong>. The company’s strong operational performance has prompted an increase in its full-year 2026 guidance, with estimated reported sales now projected at USD 101.1 billion<\/strong> (7.3% growth at the midpoint).<\/p>\n\n\n\n

Financial Performance | Q2 2026 Highlights<\/h2>\n\n\n\n
Metric<\/th>Q2 2026<\/th>YOY Change<\/th><\/tr><\/thead>
Total Sales<\/strong><\/td>USD 25.3B<\/td>+6.6%<\/td><\/tr>
US Sales<\/strong><\/td>USD 14.5B<\/td>+7.3%<\/td><\/tr>
International Sales<\/strong><\/td>USD 10.8B<\/td>+5.7%<\/td><\/tr>
Revised FY2026 Guidance<\/strong><\/td>USD 101.1B<\/td>+7.3% (midpoint)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Business Segment Performance<\/h2>\n\n\n\n

Innovative Medicine<\/h3>\n\n\n\n